- Email: [email protected]
91257926 Endometrial morphology in asymptomatic postmenopausal women
246
44 years. Baseline values were obtained cholesterol and low-density lipoprotein
in 155 women from < I year up to 30 years after menopause. cholesterol tended to rise during the early postmenopausal
Total years
while high-density lipoprotein cholesterol did not change. Triglycerides were related to weight and were significantly different only between untreated women of normal weight (128.3 f 7.80 mg/dl) and hormone users weighing >200 pounds (252.9 * 9.44 mgdl), p I 0.001. Although mean high-density lipoprotein cholesterol was lower with both C-21 progestogens (64.5 * 4.16 mg/dl) and C-19 progestogens (61.9 f 3.84 mg/dl), there were no statistically signiticant differences on comparison with levels in the unopposed estrogen users (67.0 f 3.94 mgdl). Smoking significantly depressed high-density lipoprotein cholesterol in both hormone users (p s 0.001) and untreated women (p 5 0.001). Added progestogens do not adversely affect lipids and lipoproteins over the long term when adequate dosages of estrogens
are used.
91257926 Endometrial morphology in asymptomatic postmenopausal women Archer D.F.; McIntyre-Seltman K.; Wilborn W.W. Jr.; Dowling E.A.; Cone F.; Creasy G.W.; Kafrissen M.E. Women’s Reproductive Health Unit, Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School. Norfolk, VA 23507 AM. .I. OBSTET.
GYNECOL.
1991 165/2 (317-322)
Few data are available regarding endometrial histologic features in asymptomatic perimenopausal and postmenopausal women. This study encompasses endometrial biopsy specimens obtained from 801 such women before enrollment in a multicenter study of estrogen-progestin replacement. One endometrial cancer was found (O.l3”/u); four additional biopsy specimens showed atypia (total 0.63%). The endometrium was atrophic in 373 (46.90/u), proliferative in 133 (16.7”/~), secretory in 54 (6.8%) and hyperplastic in 41 (5.2%). Insufficient tissue for diagnosis was obtained in I95 (24.5%). We conclude that the yield for neoplasia is so low that screening postmenopausal women.
endometrial
biopsy is not justified
in asymptomatic
perimenopausal
and
91266177 Fluorides and osteoporosis Kleerekoper M.; Balena R. Bone and Mineral Division, Henry Ford Hospital, Detroit, MI 48202 ANNU. REV. NUTR. 1991 II/- (309-324) Sodium fluoride has clearly been shown to have pronounced effects on the skeleton, probably more than any other currently available therapeutic agent. Unfortunately, these effects appear to be both beneficial and potentially toxic at the same time. A more clear understanding is needed of the basic mechanisms whereby these effects (both beneficial and detrimental) are exerted. When such data are forthcoming, it may be possible to modify the such that the beneficial effects Until such time, and despite sodium fluoride has no role research
therapeutic use of fluoride in osteoporosis and other brittle bone diseases outweigh the toxic effects much more completely than is currently the case. thirty years of meaningful clinical investigation, we must conclude that in clinical medicine outside the confines of properly conducted clinical
studies.
91271981 Circulating levels of calciotropic hormones during treatment with nasal salmon calcitonin Thamsborg G.; Storm T.L.; Daugaard H.; Schifter S.; Sorensen O.H. Department of Medicine, Sundby Hospital, DK-2300 Copenhagen S ACTA ENDOCRINOL. 1991 l25/2 (127-131) Circulating levels of calciotropic hormones were measured during one year of treatment with either 200 IU of salmon calcitonin daily or placebo as a nasal spray in 20 postmenopausal women with a former Colles’ fracture. A supplement of 0.5 gram elemental calcium was given to all participants, Serum levels of parathyroid hormone and human calcitonin were determined with radioimmunoassays, and serum
44 years. Baseline values were obtained cholesterol and low-density lipoprotein
in 155 women from < I year up to 30 years after menopause. cholesterol tended to rise during the early postmenopausal
Total years
while high-density lipoprotein cholesterol did not change. Triglycerides were related to weight and were significantly different only between untreated women of normal weight (128.3 f 7.80 mg/dl) and hormone users weighing >200 pounds (252.9 * 9.44 mgdl), p I 0.001. Although mean high-density lipoprotein cholesterol was lower with both C-21 progestogens (64.5 * 4.16 mg/dl) and C-19 progestogens (61.9 f 3.84 mg/dl), there were no statistically signiticant differences on comparison with levels in the unopposed estrogen users (67.0 f 3.94 mgdl). Smoking significantly depressed high-density lipoprotein cholesterol in both hormone users (p s 0.001) and untreated women (p 5 0.001). Added progestogens do not adversely affect lipids and lipoproteins over the long term when adequate dosages of estrogens
are used.
91257926 Endometrial morphology in asymptomatic postmenopausal women Archer D.F.; McIntyre-Seltman K.; Wilborn W.W. Jr.; Dowling E.A.; Cone F.; Creasy G.W.; Kafrissen M.E. Women’s Reproductive Health Unit, Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School. Norfolk, VA 23507 AM. .I. OBSTET.
GYNECOL.
1991 165/2 (317-322)
Few data are available regarding endometrial histologic features in asymptomatic perimenopausal and postmenopausal women. This study encompasses endometrial biopsy specimens obtained from 801 such women before enrollment in a multicenter study of estrogen-progestin replacement. One endometrial cancer was found (O.l3”/u); four additional biopsy specimens showed atypia (total 0.63%). The endometrium was atrophic in 373 (46.90/u), proliferative in 133 (16.7”/~), secretory in 54 (6.8%) and hyperplastic in 41 (5.2%). Insufficient tissue for diagnosis was obtained in I95 (24.5%). We conclude that the yield for neoplasia is so low that screening postmenopausal women.
endometrial
biopsy is not justified
in asymptomatic
perimenopausal
and
91266177 Fluorides and osteoporosis Kleerekoper M.; Balena R. Bone and Mineral Division, Henry Ford Hospital, Detroit, MI 48202 ANNU. REV. NUTR. 1991 II/- (309-324) Sodium fluoride has clearly been shown to have pronounced effects on the skeleton, probably more than any other currently available therapeutic agent. Unfortunately, these effects appear to be both beneficial and potentially toxic at the same time. A more clear understanding is needed of the basic mechanisms whereby these effects (both beneficial and detrimental) are exerted. When such data are forthcoming, it may be possible to modify the such that the beneficial effects Until such time, and despite sodium fluoride has no role research
therapeutic use of fluoride in osteoporosis and other brittle bone diseases outweigh the toxic effects much more completely than is currently the case. thirty years of meaningful clinical investigation, we must conclude that in clinical medicine outside the confines of properly conducted clinical
studies.
91271981 Circulating levels of calciotropic hormones during treatment with nasal salmon calcitonin Thamsborg G.; Storm T.L.; Daugaard H.; Schifter S.; Sorensen O.H. Department of Medicine, Sundby Hospital, DK-2300 Copenhagen S ACTA ENDOCRINOL. 1991 l25/2 (127-131) Circulating levels of calciotropic hormones were measured during one year of treatment with either 200 IU of salmon calcitonin daily or placebo as a nasal spray in 20 postmenopausal women with a former Colles’ fracture. A supplement of 0.5 gram elemental calcium was given to all participants, Serum levels of parathyroid hormone and human calcitonin were determined with radioimmunoassays, and serum